Compare Globus Medical Inc. Class A Common Stock (GMED) vs Hudbay Minerals Inc. Ordinary Shares (Canada) (HBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Hudbay Minerals Inc. Ordinary Shares (Canada) — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Hudbay Minerals Inc. Ordinary Shares (Canada) trades at $23.89 (market cap $11.37B). The key difference: Globus Medical Inc. Class A Common Stock and Hudbay Minerals Inc. Ordinary Shares (Canada) are close in size by market cap, and Hudbay Minerals Inc. Ordinary Shares (Canada) pays a 0.11% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Hudbay Minerals Inc. Ordinary Shares (Canada) for 6 Days on average.
| GMED | HBM | |
|---|---|---|
Market Cap | $10.25B | $11.37B |
Volume | 1,108,124 | 3,520,423 |
Sector | Health | Basic Materials |
52-Week High | $96.82 | $31.87 |
52-Week Low | $58.33 | $14.58 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $11.43B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
HudBay Minerals (HBM) trades at $25.68, down 0.31% with bearish technical signals despite solid fundamentals. The company reported strong 2025 results with $2.21B revenue and $568.5M net income, while analyst consensus remains positive with 60% buy ratings. Recent news highlights HBM4 equipment delays and copper/gold reserve expansions at Snow Lake operations.
HBM presents a value opportunity with reasonable valuation (P/E 15.77) and strong profitability (ROE 18.43%), though technical weakness and HBM market dynamics pose near-term risks. The stock's outlook depends on execution of copper growth strategy and resolution of memory sector supply chain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Hudbay Minerals Inc. Ordinary Shares (Canada)
Hudbay Minerals is a mining company producing copper, gold, zinc, and other metals. Its operations are located in the Americas.
Read more on HBM →
